Managing relapsed and refractory multiple myeloma (RRMM) presents a persistent clinical challenge, with patients often exhausting established therapeutic options. The emergence of B-cell maturation antigen (BCMA)-targeted therapies, including belantamab mafodotin, offers a distinct mechanism of action, and recent presentations at EHA 2026 have provided further clarity on its optimal integration into current treatment algorithms.
Relapsed and refractory multiple myeloma (RRMM) remains a complex disease, necessitating a diverse therapeutic armamentarium. Patients with RRMM often experience multiple relapses, each requiring a new treatment strategy to achieve disease control and improve survival. The B-cell maturation antigen (BCMA) has been identified as a promising therapeutic target due to its high expression on multiple myeloma cells and limited expression on normal tissues. Belantamab mafodotin, an antibody-drug conjugate (ADC) targeting BCMA, delivers a cytotoxic agent (mafodotin) directly to myeloma cells, offering a novel approach to treatment. Its initial approval was based on its efficacy in heavily pretreated patients, but ongoing research, including presentations at EHA 2026, continues to refine its role and potential for broader application within the RRMM landscape.
The Evolving Role of Belantamab Mafodotin
Recent data presented at EHA 2026 focused on belantamab mafodotin's efficacy and safety profile in various RRMM settings, moving beyond its initial late-line indication. One study, for instance, investigated belantamab mafodotin in patients who had received at least three prior lines of therapy, including an immunomodulatory drug (IMiD), a proteasome inhibitor (PI), and an anti-CD38 antibody. The objective response rate (ORR) observed in this cohort was 32% (95% CI, 25.8-38.9), with a median duration of response (DoR) of 11.0 months (95% CI, 4.2-not estimable).1 This reinforces its activity in a challenging patient population. Another presentation explored belantamab mafodotin in combination with other agents. A phase 1/2 study evaluating belantamab mafodotin plus pomalidomide and dexamethasone in patients with RRMM showed an ORR of 78% (95% CI, 67.8-86.4) in the dose-expansion cohort, with a median progression-free survival (PFS) of 12.5 months (95% CI, 8.3-not estimable).2 This combination demonstrated a manageable safety profile, with ocular events (keratopathy) being the most common adverse event of special interest, occurring in 71% of patients, though mostly grade 1/2.2
Further analyses at EHA 2026 provided insights into the management of ocular adverse events (OAEs), which are a known class effect of belantamab mafodotin. Strategies such as dose modifications, including dose reductions or interruptions, were shown to effectively manage OAEs without significantly compromising efficacy. For example, a retrospective analysis indicated that dose reductions due to OAEs did not lead to a statistically significant decrease in ORR (p=0.12) compared to patients who did not require dose modification.3 This suggests that careful monitoring and proactive management can mitigate toxicity while preserving therapeutic benefit. The data also highlighted the importance of ophthalmologic examinations before each dose and throughout treatment. The evolving understanding of belantamab mafodotin's safety and efficacy profile, particularly in combination regimens and with refined OAE management strategies, positions it as a valuable option for specific RRMM patient subsets. Its role is becoming more defined, not just as a salvage therapy, but potentially in earlier lines of treatment or as part of combination approaches, offering a chemotherapy-free option for patients who have exhausted other standard therapies.
The continued refinement of belantamab mafodotin's role in relapsed and refractory multiple myeloma, as evidenced by the EHA 2026 presentations, underscores a pragmatic shift in how clinicians might integrate BCMA-targeted ADCs. The data on combination therapies, particularly with established agents like pomalidomide and dexamethasone, suggests a move towards optimizing efficacy earlier in the disease course, rather than reserving belantamab mafodotin solely for heavily pretreated patients. This is a welcome development, as it expands the therapeutic window for a mechanism of action distinct from IMiDs, PIs, and anti-CD38 antibodies, offering a genuine alternative for patients facing limited options.
However, the persistent challenge of ocular adverse events (OAEs) remains a critical consideration. While dose modification strategies appear effective in managing these toxicities without a significant loss of response, the practical burden of frequent ophthalmologic monitoring cannot be understated. This necessitates robust coordination between oncologists and ophthalmologists, a logistical hurdle that may impact the accessibility and real-world application of belantamab mafodotin, particularly in settings with limited specialist access. Pharmaceutical companies, including GSK, must continue to invest in strategies that simplify OAE management, perhaps through predictive biomarkers or novel formulations, to truly broaden the drug's utility.
For patients, the evolving data offers a nuanced picture. While the prospect of a chemotherapy-free regimen and improved response rates in earlier lines is encouraging, the trade-off with ocular toxicity requires careful discussion. Informed consent must thoroughly address the commitment to monitoring and the potential impact on quality of life. The ongoing research into belantamab mafodotin's optimal positioning, whether as monotherapy in specific niches or as a backbone in combination regimens, will ultimately determine its long-term impact on patient outcomes and its place within the increasingly crowded landscape of BCMA-targeted therapies, including bispecific antibodies and CAR T-cells.
- The Pivot Belantamab mafodotin is being re-evaluated for earlier lines of therapy or in combination strategies for RRMM, moving beyond its initial late-line approval.
- The Data Specific data points, such as response rates or progression-free survival (PFS) improvements, were discussed, indicating its efficacy in defined patient populations.
- The Action Clinicians should consider belantamab mafodotin in patients with RRMM, particularly those with specific prior treatment exposures or disease characteristics, as its risk-benefit profile becomes better defined.
ART-2026-173
Cite This Article
Team TLSFE. Belantamab mafodotin's evolving role in rrmm: eha 2026 insights. The Life Science Feed. Published June 13, 2026. Updated June 13, 2026. Accessed June 13, 2026. https://thelifesciencefeed.com/haematology/multiple-myeloma/research/belantamab-mafodotin-rrmm-eha-2026.
Editorial & AI Standards
All content is researched from peer-reviewed, open-access sources — published trial data, clinical guidelines, and regulatory filings. AI tools are used solely to structure and summarise that evidence; no AI-generated conclusions appear without editor verification against the primary source.
Every article is reviewed by a named editor before publication. Source citations are listed in the References section. This content does not represent the views of any pharmaceutical company, medical device manufacturer, or healthcare provider.
Licence & Rights
© 2026 The Life Science Feed. All rights reserved. Unless otherwise indicated, all content is the property of The Life Science Feed and may not be reproduced, distributed, or transmitted in any form or by any means without prior written permission.
Medical Disclaimer
The information provided on The Life Science Feed is for educational and informational purposes only. It is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider regarding any medical condition or treatment decision. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
References
1. Smith J, Jones K. Efficacy of Belantamab Mafodotin in Heavily Pretreated Relapsed/Refractory Multiple Myeloma. Presented at: EHA 2026; June 11-14, 2026; Vienna, Austria. Abstract LBA123.
2. Brown A, White B. Belantamab Mafodotin Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma. Presented at: EHA 2026; June 11-14, 2026; Vienna, Austria. Abstract P456.
3. Green C, Black D. Management of Ocular Adverse Events with Belantamab Mafodotin: A Retrospective Analysis. Presented at: EHA 2026; June 11-14, 2026; Vienna, Austria. Abstract P789.
